GHRP-6: The Drug Came First, the Hormone Came Fifteen Years Later

The doorbell, the door, and the visitor

GHRP-6 is a synthetic string of six amino acids, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Bowers and colleagues described it in Endocrinology in 1984 as [His1,Lys6] GHRP, in rats, monkeys, lambs, calves and chicks, reporting growth hormone release with no concomitant release of LH, FSH, TSH or prolactin (PMID 6714155). Hold on to that last part.

When Bowers built it, nobody knew what it bound to. The growth hormone secretagogue receptor was not cloned until 1996, by Howard and colleagues, who found it by chasing these synthetic peptides backwards, and ghrelin, the hormone the body makes for it, was not identified until Kojima and colleagues got there in 1999, fifteen years after the peptide. Somebody built a doorbell. Then somebody found the door it rang. Then somebody worked out who had been pressing it. The field calls this reverse pharmacology.

The numbers everything else reuses

Bowers 1990 is the founding human study: 18 normal men, intravenous bolus at 0.1, 0.3 and 1.0 mcg/kg against placebo, peak serum growth hormone of 1.2 mcg/L on placebo and then 7.6, 16.5 and 68.7 mcg/L up the ladder (PMID 2108187). Prolactin, LH, TSH and cortisol went in as a specificity check, and this is where the 1984 animal result comes apart: prolactin and cortisol each rose about two fold above baseline, only at the top 1 mcg/kg rung, while LH and TSH did not move over the first hour. The canonical dose and the dose at which the compound stops being selective are the same dose.

The only published human IGF-1 rise on GHRP-6 alone came out of a 34 hour infusion in nine healthy young men, a 1 mcg/kg intravenous bolus then 1 mcg/kg per hour, where growth hormone pulse amplitude roughly doubled and plasma IGF-1 went from 252 to 312 mcg/L (PMID 7903313). The half life everybody quotes, 2.5 plus or minus 1.1 hours, is from the same route: nine healthy men, single intravenous boluses at 100, 200 and 400 mcg/kg (PMID 23099431).

The vein is not the only route that has been through people. Ten normal men swallowed GHRP-6 at 30, 100 and 300 mcg/kg and were also given 1 mcg/kg intravenously, and peak growth hormone came out at 4.0 mcg/L on placebo, then 5.2, 9.2 and 18 mcg/L up the oral ladder against 26 mcg/L from the vein, so swallowing it works at roughly three hundred times the intravenous dose (PMID 1592884). Swallowed, or into a vein. Neither is the needle under the skin that everybody actually uses.

The hunger I could not find measured

I could not find a single published human study that measured appetite, hunger ratings or food intake after GHRP-6. Run the search yourself on PubMed, GHRP-6 with appetite or food intake: 98 records, all animal work, reviews, or studies of [D-Lys3]-GHRP-6, which is the blocker rather than the drug. Every human figure in circulation, the share of users it hits, the onset, the duration, is vendor copy with nothing under it.

The evidence is rodent. Female Wistar rats given 250 mcg/kg under the skin twice daily for two weeks ate more for up to seven hours after a single injection and put on 15 percent inguinal and 20 percent visceral mesenteric fat pad weight (PMID 15191362), and the better half of that study is its control condition: in adrenalectomised rats given no corticosterone replacement the appetite effect disappeared at every time point. Basal glucocorticoid has to be there for the hunger to happen.

What else moves

The adrenal axis moves reliably enough that GHRP-6 was trialled as a diagnostic test for adrenal insufficiency, in 49 patients with suspected pituitary adrenal dysfunction plus 20 healthy controls at 1 mcg/kg, route not stated in the abstract, where mean peak cortisol came out at 227 nmol/l in the adrenal insufficient group against 395 nmol/l in the sufficient one (PMID 19946832).

The largest published human interventional trial, a Cuban randomised phase I/II in 36 acute ischaemic stroke patients, gave GHRP-6 at 3.5 or 5 mg intravenously twice daily for 7 days, always paired with epidermal growth factor (Hernandez-Bernal 2024), so nothing in it can be assigned to GHRP-6. More people than that have had GHRP-6 in a single published study, 69 of them, in that adrenal insufficiency work, but that was single dose provocation testing rather than a treatment trial.

Where 100 mcg came from

The recurring published human dose is 1 mcg/kg into a vein. Bowers 1990 set it as the top rung, and Borges 1997, Pandya 1998, Muller 2001, Micic 2002 and Alaioubi 2010 all reused that dose and that route exactly. For an 80 to 100 kg man that is 80 to 100 mcg, which lands on the flat 100 mcg the community uses. The convention that circulates is 100 to 300 mcg under the skin, two to three times daily, on an empty stomach, in runs of 8 to 16 weeks, so 200 to 900 mcg a day, and the community pages put saturation near 1 mcg/kg, crediting that ceiling to Bowers 1990, which does show the two fold prolactin and cortisol rise only at the top rung.

The transfer is the part nobody has validated. That published dose is a single intravenous bolus for acute provocation, the convention is repeated injection under the skin for weeks, and I found no human subcutaneous pharmacokinetic study, no subcutaneous dose response, and no study of repeated daily subcutaneous dosing of GHRP-6 alone. The only human subcutaneous exposure on record is a retrospective look at 14 hypogonadal men on testosterone, no control group, who took GHRP-6 alongside GHRP-2 and sermorelin, 100 mcg of each, three times daily for an average of 134 days, with serum IGF-1 rising from 159.5 to 239.0 ng/mL (PMID 28830317). Three compounds went in at once.

What I could not find

I found no human head to head against GHRP-2 on prolactin, cortisol, ACTH, growth hormone or appetite, and that is the load-bearing absence: the vendor line that GHRP-6 is the dirtier of the two rests on a comparison I could not locate. The multi month growth study people cite for GHRP-6 is not GHRP-6 either: six prepubertal growth hormone deficient children on stepwise subcutaneous doses of 0.3, 1.0 and 3.0 mcg/kg/day over eight months, growth velocity rising while IGF-1 and IGFBP-3 did not, used GHRP-2 (PMID 9661608). Different molecule. Its evidence is not this one's evidence.

One thing you can check yourself: doping control chemists found Gly-GHRP-6, the peptide with an extra glycine on the front, in black market products (PMID 29864719). Monoisotopic 872.44 plus glycine's 57.02 puts the substitute near 929.46 neutral, arithmetic on published masses rather than a figure from that paper.

Regulatory status

WADA names GHRP-6 explicitly on the 2026 Prohibited List under S2.2.4, growth hormone releasing factors, prohibited at all times, in and out of competition, and non-Specified, which is the more serious tier. FDA has said two different things about the same molecule. On the 503A list for pharmacy compounding, dated 29 September 2023, it is Category 3, nominated without adequate support, meaning nobody submitted enough for FDA to evaluate it. On the 503B list for outsourcing facilities, updated 21 March 2025, it is Category 2, substances that raise significant safety risks, listed flatly with no route exemption. I found no evidence it is approved for human use in any jurisdiction.

My opinion

The shape of the record is what I keep coming back to. This compound was built before anyone knew what it bound to or what the body's own version of it was, it has been going into humans since 1990, and the one effect people buy it for is the one I could not find measured in a person. Not measured badly. Not measured at all, in anything I could find. The effects nobody wants, cortisol and prolactin, are the ones carrying human numbers, and they turn up at the same 1 mcg/kg the whole field treats as standard.

Because GHRP-6 led researchers to ghrelin, it also gets sold as though it were ghrelin, and the hunger is offered as proof the thing is working. Micic 2002 is the correction. Six normal subjects, ghrelin and GHRP-6 both at 1 mcg/kg into a vein, and the real hormone peaked at 39.9 mcg/L of growth hormone against 18.4 (PMID 12457451).

If you have run GHRP-6, I want to know one specific thing. Did the hunger arrive on the first injection or build over the first week, and did you ever change your dose because of it rather than anything else you were tracking?

---

This content is for educational and informational purposes only and is not medical advice. Peptides discussed are research compounds and may not be approved for human use. Nothing here should be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any peptide, supplement, or protocol. Individual responses vary. Do not self-administer compounds without proper medical supervision.